TSPO PET With 18F-GE-180 to Differentiate Variants of Multiple Sclerosis: Relapsing-Remitting Multiple Sclerosis, Tumefactive Demyelination, and Baló's Concentric Sclerosis.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
17
8
2020
medline:
11
11
2020
entrez:
16
8
2020
Statut:
ppublish
Résumé
PET targeting the translocator protein (TSPO) expression is an interesting approach to detect neuroinflammation, as TSPO is upregulated in activated macrophages and microglia. Considering the variable pathophysiology of multiple sclerosis (MS) variants, we compare TSPO PET using F-GE-180 in 3 different demyelinating diseases of the central nervous system: relapsing-remitting MS, tumefactive MS, and Baló's concentric sclerosis. Visualization of neuroinflammation and its PET patterns in addition to MRI may contribute to accurate distinction and monitoring of central nervous system demyelination.
Identifiants
pubmed: 32796248
doi: 10.1097/RLU.0000000000003220
pii: 00003072-202010000-00037
doi:
Substances chimiques
Carbazoles
0
GE-180
0
Receptors, GABA
0
TSPO protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e447-e448Références
Bolcaen J, Acou M, Mertens K, et al. Structural and metabolic features of two different variants of multiple sclerosis: a PET/MRI study. J Neuroimaging. 2013;23:431–436.
Hardy TA, Tobin WO, Lucchinetti CF. Exploring the overlap between multiple sclerosis, tumefactive demyelination and Balo’s concentric sclerosis. Mult Scler. 2016;22:986–992.
Sridharan S, Raffel J, Nandoskar A, et al. Confirmation of specific binding of the 18-kDa translocator protein (TSPO) radioligand [(18)F]GE-180: a blocking study using XBD173 in multiple sclerosis normal appearing white and grey matter. Mol Imaging Biol. 2019;21:935–944.
Vomacka L, Albert NL, Lindner S, et al. TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Res. 2017;7:89.
Unterrainer M, Mahler C, Vomacka L, et al. TSPO PET with [(18)F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis. Eur J Nucl Med Mol Imaging. 2018;45:1423–1431.
Stadelmann C, Ludwin S, Tabira T, et al. Tissue preconditioning may explain concentric lesions in Balo’s type of multiple sclerosis. Brain. 2005;128(Pt 5):979–987.
Hardy TA, Miller DH. Balo’s concentric sclerosis. Lancet Neurol. 2014;13:740–746.
Albert NL, Unterrainer M, Brendel M, et al. In response to: the validity of (18)F-GE180 as a TSPO imaging agent. Eur J Nucl Med Mol Imaging. 2019;46:1208–1211.
Unterrainer M, Fleischmann DF, Lindner S, et al. Detection of cerebrospinal fluid dissemination of recurrent glioblastoma using TSPO-PET with 18F-GE-180. Clin Nucl Med. 2018;43:518–519.